Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics, Inc. (ELTX) is a clinical-stage biotechnology company pioneering lymph node-targeted immunotherapies through its proprietary AMP platform. This dedicated news hub provides investors and industry observers with timely updates on ELTX's progress in developing novel cancer treatments.
Access official press releases, clinical trial milestones, and corporate developments related to ELTX's innovative pipeline. Track updates on KRAS-targeted vaccines, AMP platform advancements, and strategic collaborations. Our curated collection includes regulatory filings, peer-reviewed research highlights, and financial disclosures essential for informed analysis.
Key focus areas include clinical progress updates, partnership announcements, intellectual property developments, and scientific presentations. This resource serves investors seeking to monitor ELTX's position in the competitive immunotherapy landscape while staying informed about its novel approach to enhancing T cell responses against aggressive cancers.
Bookmark this page for streamlined access to verified ELTX developments. Check regularly for updates on the company's mission to transform cancer treatment through precision immune system engagement.
Elicio Therapeutics (Nasdaq: ELTX) reported updated immunogenicity from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical intratumoral data for ELI-004 presented at SITC (Nov 7, 2025).
Key clinical highlights: 99% of 90 evaluable patients mounted mKRAS-specific T cell responses (mean 145-fold increase), 86.8% (66/76) induced cytotoxic responses, 85% showed combined CD4/CD8 activation, and 88% responded to their own tumor mutation. HLA typing across 89 patients found 1,132 unique alleles with no clear HLA-specific loss of response. Preclinical ELI-004 intratumoral dosing eradicated tumors in >90% of mice and conferred long-term protection.
Elicio Therapeutics (Nasdaq: ELTX) will present clinical and preclinical data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5–9, 2025, in National Harbor, MD.
Two poster presentations include a late-breaking abstract reporting immunogenicity results from the ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in mKRAS-driven pancreatic cancer (Abstract 1317; Nov 7, 2025) and preclinical data for ELI-004 showing AMP-immunomodulator activity in syngeneic solid tumor models (Abstract 946; Nov 8, 2025).
Elicio Therapeutics (Nasdaq: ELTX) reported preliminary Phase 2 AMPLIFY-7P results showing that ELI-002 7P induced mKRAS-specific T cell responses across diverse HLA backgrounds.
Among 89 patients, 1,132 unique HLA types were identified out of 1,398 total HLA types assessed, and 99% (88/89) of patients assessed for HLA background mounted mKRAS-specific T cell responses after treatment. The company said these findings suggest mKRAS antigens can be presented across many HLA alleles, implying potential applicability to a broad population of pancreatic ductal adenocarcinoma (PDAC) patients.
Results are described as preliminary and come from an ongoing Phase 2 study; additional data and follow-up were not provided.
Elicio Therapeutics (NASDAQ:ELTX) has announced a significant advancement in pancreatic cancer treatment with a new Phase 1 investigator-initiated trial for their immunotherapy drug ELI-002 7P. The study, led by Memorial Sloan Kettering Cancer Center and funded by the Lustgarten Foundation, will evaluate ELI-002 7P in combination with chemotherapy (mFOLFIRINOX) and an anti-PD1 checkpoint inhibitor.
The trial will focus on borderline and resectable pancreatic ductal adenocarcinoma (PDAC) patients, enrolling 20 patients across two cohorts (10 per arm). The study aims to convert immunologically "cold" tumors to T-cell-inflamed "hot" tumors, potentially improving surgical outcomes and long-term survival. The trial is expected to begin in H1'2026.
Elicio Therapeutics (Nasdaq: ELTX) has granted 9,800 inducement stock options to two new employees on September 15, 2025. The options were priced at $10.08 per share with a four-year vesting schedule, starting with 25% vesting after the first year.
The company, specializing in novel immunotherapies for cancer treatment, highlighted its lead program ELI-002, an off-the-shelf vaccine targeting KRAS mutations. Recent Phase 1 AMPLIFY-201 data showed promising results with 16.3-month median recurrence-free survival and 28.9-month median overall survival in pancreatic and colorectal cancer patients.
Elicio Therapeutics (NASDAQ:ELTX) reported impressive immunogenicity data from its ongoing Phase 2 AMPLIFY-7P trial for ELI-002 7P, its investigational vaccine immunotherapy. The trial demonstrated that 99% of evaluable patients (89 of 90) generated strong mKRAS-specific T cell responses, with an average increase of 145.3x over baseline.
Key highlights include 85% of patients showing both mKRAS-specific CD4 and CD8 T cells, and 87.6% of patients demonstrating response to their specific tumor antigen. The results are consistent with previous Phase 1 trials, where T cell responses correlated with clinical activity in minimal residual disease positive (MRD+) patients. The final disease-free survival analysis is expected in Q4 2025.
Elicio Therapeutics (NASDAQ:ELTX) announced updated Phase 1 AMPLIFY-201 follow-up data for ELI-002 published in Nature Medicine. At 19.7 months median follow-up, the study showed significant improvements in survival metrics for minimal residual disease-positive, adjuvant-stage patients.
Key findings include median overall survival increasing to 28.94 months from 16.33 months, with patients showing T cell responses above threshold experiencing a 77% reduction in death risk and 88% reduction in relapse risk. The treatment demonstrated strong efficacy with 84% of patients showing mKRAS-specific T cell responses and tumor biomarker responses.
The final disease-free survival analysis for the Phase 2 AMPLIFY-7P study in pancreatic ductal adenocarcinoma is expected in Q4 2025. The therapy was well-tolerated with no safety concerns or dose-limiting toxicities reported.
Elicio Therapeutics (NASDAQ:ELTX) reported Q2 2025 financial results and provided updates on its cancer immunotherapy pipeline. The Independent Data Monitoring Committee (IDMC) recommended continuing the ELI-002 7P Phase 2 study in pancreatic cancer without modifications, with final disease-free survival (DFS) analysis expected in Q4 2025.
Financial highlights include a $10 million non-dilutive financing secured in June 2025. Q2 2025 showed R&D expenses of $7.0 million (down from $8.2M in Q2 2024) and a net loss of $10.6 million. Cash position of $22.1 million is expected to fund operations into Q1 2026, beyond the anticipated Phase 2 final analysis.
The company plans to request an End-of-Phase 2 FDA meeting to finalize the regulatory strategy for ELI-002's pivotal Phase 3 trial following the final DFS analysis.
Elicio Therapeutics (NASDAQ:ELTX) announced that the Independent Data Monitoring Committee (IDMC) has recommended continuing the Phase 2 AMPLIFY-7P study of ELI-002 7P for pancreatic cancer without modifications. The trial, involving 144 patients across 24 U.S. sites, evaluates ELI-002 7P's effectiveness against standard of care in improving disease-free survival (DFS) for pancreatic ductal adenocarcinoma (PDAC) patients.
The IDMC's positive recommendation suggests preliminary efficacy signals and confirms a favorable safety profile. The final DFS analysis is expected in Q4 2025. Notably, Elicio has already aligned with the FDA on key elements of the planned Phase 3 study design and maintains a cash runway extending into Q1 2026.
FAQ
What is the current stock price of Elicio Therapeutics (ELTX)?
What is the market cap of Elicio Therapeutics (ELTX)?
